Table 2.

Treatment characteristics.

	n = 437 [%]
Time primary diagnosis until radiation therapy start (weeks)
mean	11.1
median	10
standard deviation	6.9
quartile 1–quartile 3	5.3–16.1
minimum-maximum	0–33
Time chemotherapy start until radiation therapy start (weeks)
mean	7.2
median	5.5
standard deviation	6.2
quartile 1–quartile 3	2–12
minimum-maximum	0–26.9
Time primary diagnosis until radiochemotherapy end (weeks)
mean	17.4
median	16.3
standard deviation	7.2
quartile 1–quartile 3	11.9–22.6
minimum-maximum	0–40
Time radiochemotherapy end until first imaging follow-up (weeks)
mean	3.8
median	3.4
standard deviation	n.a.
quartile 1–quartile 3	0–5.7
minimum-maximum	0–16.3
Specification of radiochemotherapy end
regular end	387	[88.6%]
regular dose	362	[82.8%]
dose reduction	25	[5.7%]
premature end	50	[11.4%]
therapy related toxicity	14	[3.2%]
disease progression	15	[3.4%]
other reasons	21	[4.8%]
Major interruptions of radiation therapy (>3 days)
no	319	[73.0%]
yes	118	[27.0%]
Duration interruptions of radiation therapy (days)
mean	2.7
median	2
standard deviation	3.21
quartile 1–quartile 3	0–4
minimum-maximum	0–9
Radiotherapy total dose (cGy)
mean	6198
median	6000
standard deviation	321.7
quartile 1–quartile 3	6,000–6,600
minimum-maximum	5,400–6,600
Platinum-based chemotherapy
Cisplatin	223	[51.4%]
Carboplatin	211	[48.6%]
Platinum-based chemotherapy combination partner
Alimta	8	[1.8%]
Docetaxel	1	[0.2%]
Etoposide	18	[4.1%]
Gemcitabine	25	[5.7%]
nab-Paclitaxel	1	[0.2%]
Paclitaxel	9	[2.1%]
Permetrexed	3	[0.7%]
Vincristin	1	[0.2%]
Vinorelbine	371	[84.9]
Number of platinum-based chemotherapy cycles
mean	2.93
median	3
standard deviation	1.19
quartile 1–quartile 3	2–4
minimum-maximum	0–8